Comparatives Tudy Of Second-line Treatment Of Advanced Colorectal Cancer With TOMIRI And FOLFIRI Regimen

Objective:To observe the efficacy and tolerability of irinotecan combination with raltitrexed(TOMIRI)in the treatment of patients with advanced colorectal cancer,and compare it with the FOLFIRI regimen.Analyze the advantages and disadvantages of these two treatments and provide guidance for the clinic.Clinical data and methods:Retrospective analysis of patients with advanced colorectal patients who received fluorouracil combined with oxaliplatin in the firstline.All selected from the Second Affiliated Hospital of Nanchang University from April 2017 to March 1919.Result:There were no patients with CR in both groups.In the observation group,6patients achieved PR,14 patients achieved SD,and 10 patients had PD.In the control group,4 patients achieved PR,8 patients achieved SD,and 18 patients had PD.The RR of the observation group and the control group were 20.00% and13.33%(p=0.729),and the DCR were 66.67% and 40.00%(p=0.038).The Log Rank test between the two groups was p=0.70.There was no statistically significant difference.There were no treatment-related deaths in the two groups.Adverse reactions were mainly gastrointestinal reactions,myelosuppression,and abnormal liver and kidney function.Among the adverse reactions in the experimental group were as follows,4 cases of grade III/IV neutropenia,2 cases of grade III/IV anemia,7cases of grade III/IV nausea and vomiting,2 cases of grade III diarrhea and nausea and vomiting.There were 7 grade III/IV neutropenia,5 grade III/IV thrombocytopenia,3 grade III/IV anemia,8 grade III nausea and vomiting,and 2grade III/IV diarrhea in the control group.One patient in the control group developed more severe oral mucositis,and the symptoms were relieved after prolonged treatment cycle and local symptomatic treatment.In the control group,2 patients were found to have palpitations after treatment,and ECG showed supraventricularTachycardia.There was no significant difference in the overall incidence of toxic and side effects and the incidence of serious adverse reactions between the two groups(P>0.05).Result:1.The TOMIRI regimen is safe and feasible compared with the second-line treatment of colorectal cancer in the second-line treatment of FOLFIRI,without increasing the incidence of adverse reactions.2,TOMIRI program compared with FOLFIRI second-line treatment of patients with advanced colorectal cancer,the disease control rate is significantly better than the latter,but the overall efficiency has no significant difference,TTP prolongation is not significant.This program can be used as a second-line solution for patients with advanced colorectal.